ArticleEMBO reports2007
Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein.
Article in EMBO reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- EPYC promotes laryngeal cancer carcinogenesis and angiogenesis by docking to VEGFR1: A novel therapeutic target.iScience · 2025Article
- VEGFR1 as a Target for Cardiovascular Gene Therapy.Journal of cardiovascular translational research · 2025Review
- Coagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivo.Blood · 2024Article
- VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content.EMBO reports · 2020Article
- Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review.Cardiovascular research · 2018 · on this mapReview
- Angiogenesis in the atherosclerotic plaque.Redox biology · 2017Review
- Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.CEN case reports · 2016Article
- Mechanisms and regulation of endothelial VEGF receptor signalling.Nature reviews. Molecular cell biology · 2016Review
- Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.Cancer letters · 2015Article
- Canonical and noncanonical vascular endothelial growth factor pathways: new developments in biology and signal transduction.Arteriosclerosis, thrombosis, and vascular biology · 2015Review
- ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1.Nature medicine · 2012Article
- Logical structures extracted from metastasis experiments.Cancer science · 2009Review
- On the relationship of LDL and VEGFR1: not just a family affair.EMBO reports · 2007Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated serum low-density lipoprotein (LDL) is a risk factor for atherosclerotic disorders. However, prominent atherosclerosis, which has been observed in LDL receptor (LDLR)-knockout mice, has diminished the significance of LDLR as a cause of atherosclerosis, while elaborate studies have focused on the receptors for denatured LDL. Here we report that native LDL (nLDL) activates vascular endothelial growth factor (VEGF) receptor 1 (VEGFR1) but not VEGFR2 through LDLR and is as potent as VEGF in macrophage migration. Binding and co-endocytosis of VEGFR1 and LDLR were enhanced by nLDL, which is concomitant with ubiquitination-mediated degradation of VEGFR1. We propose that LDLR-mediated use of VEGFR1 by nLDL could be a potential therapeutic target in atherosclerotic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.